| Literature DB >> 32726990 |
Sandra Martín-Peláez1,2, Montse Fito3,4, Olga Castaner3,4.
Abstract
The search for a quality diet has grown over the past decade. Diet is considered one of the pillars for the prevention and progression of several diseases, among them: diabetes. Type 2 diabetes (T2D) is an epidemic of western countries that increases the vulnerability of other diseases, such as cardiovascular and cancer. T2D is associated with lifestyle and diet. The traditional Mediterranean diet has proven its benefits over several cardiovascular risk factors, and specifically on diabetes. This review compiles recent published evidence on the effects of the Mediterranean diet on the incidence and progression of type 2 diabetes (T2D) and its relation with several other cardiovascular healthy diets. We will also focus on how the Mediterranean diet could play a role in T2D-related mechanisms, such as anti-inflammatory or antioxidant compounds, glucagon-like peptide agonist compounds, and changes in gut microbiota. Each component of the Mediterranean diet could be involved in processes related to diabetes homeostasis, many of them sharing common physio-pathological pathways. The importance of this diet within the set of habits of a healthy lifestyle must be emphasized.Entities:
Keywords: Mediterranean; diabetes; mechanisms; primary prevention; quality diet
Year: 2020 PMID: 32726990 PMCID: PMC7468821 DOI: 10.3390/nu12082236
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Systematic reviews and meta-analysis of the association between Mediterranean diet and type 2 diabetes (T2D).
| First Author; Year | Type of Study | Type of Intervention | Population | Follow-up | Quality of the Studies | Output [s] | Results |
|---|---|---|---|---|---|---|---|
| Jannasch, F.; 2017 | SR, MA | MD, DASH, AHEI | Non-diabetic healthy adults | 4.1–23 years | 27 high quality | Incidence T2D | Adherence to MD (RR quantiles: 0.87; 95% CI: 0.82, 0.93), DASH (RR: 0.81; 95% CI: 0.72, 0.92), and AHEI (RR: 0.79; 95% CI: 0.69, 0.90) associated with a decreased risk of T2D. |
| Schwingshackl, L.; 2015 | SR, MA | MD | Healthy adults or with CV risk factors | 3.2–20 years | Quality moderate | Incidence T2D | Adherence to MD high vs. low. RR: 0.81; 95% CI 0.73, 0.90, p < 0.0001 associated with a decrease in T2D incidence. |
| Koloverou, E.; 2014 | SR, MA | MD | Healthy adults with or without CV/T2D | 3.5–14 years | Publication bias | Incidence T2D | High adherence to MD was associated with a 23% decreased risk of T2D, comparing the highest vs. lowest punctuation of MD RR = 0.77, 95% CI: 0.66, 0.89. |
| Esposito, K.; 2014 | MA | MD | Adults >20 y | 3.2–23 years | High heterogenicity. No publication bias. | Incidence T2D | Healthy diet RR: 0.80 (95% IC 0.74–0.86). MD vs. DASH: no changes in incidence of T2D. |
| Esposito, K.; 2015 | SR | MD | Adults with T2D or at risk | >6 months | MA: moderate | Incidence T2D Glycemic control | MD decreases HbA1c in 0.3–0.47% compared to low fat-diet. High MD adherence decreases T2D by 19–23%. |
| Schwingshackl, L.; 2018 | SR, MA | Low-fat diet or vegan, MD, LC, paleolithic hyperprotein diet | Adults with T2D | 3–48 months | Low, moderate credibility | Glycemic control HbA1c | Compared to a low fat-diet, there is a decrease in HbA1c in MD (−0.32, 95% −0.53, −0.11) and LC (−0.35, 95% −0.56, −0.14), and a decrease of glycemia in MD (−0.59 mmol/l, 95% −1.13, −0.04). |
| Emadian, A.; 2015 | SR | MD, | Overweight adults (IMC ≥25 kg/m2) and T2D | >6 months | Low medication control | Glycemic control HbA1c | MD, vegan, and low glycemic index diets improve HbA1c levels. |
| Huo, R.; 2015 | MA | MD | Adults with T2D. | 1 month–4 years | 5 low quality studies and 4 high quality. No publication bias for HOMA (Begg’s test), but for HbA1c (p = 0.001, Egger’s test) | Glycemic control HbA1c, insulin, HOMA | Compared to the control group, MD decreased HbA1c (median difference −0.30; 95% CI −0.46, −0.14), glucose (−0.72 mmol/l; CI −1.24, −0.21), and baseline insulin (−0.55 μU/ml; CI −0.81, −0.29). |
| Carter, P.; 2014 | SR, MA | MD, | Overweight and/or high CV risk and/or T2D | 2–12 months | Few studies | Glycemic control HbA1c, insulin. | MD decreased HbA1c compared to the control group, but not to the paleo diet. None of the interventions was better than the other in terms of basal glucose. |